Citation: | LI Xiaoyu, ZHANG Yongyong, QIN Juan, YANG Zhongxin. Changes of serological indexes and prognosis of acute coronary syndrome patients after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 60-62, 67. DOI: 10.7619/jcmp.20231532 |
To investigate the levels of N-terminal probrain natriuretic peptide (NT-proBNP), thrombolomodulin (TM), C-type lectin-like receptor 2 (CLEC-2), galectin-3 (Gal-3) and their relationships with prognosis in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI).
A total of 80 patients with ACS were selected as study objects. The patients were followed up for 6 months by outpatient visit or telephone follow-up, and the occurrence of major adverse cardiovascular events (MACE) was recorded in the patients. According to the occurrence of MACE, patients were divided into MACE group (26 cases) and control group (54 cases). The changes of serological indexes were compared between the two groups.
The expression levels of NT-proBNP, CLEC-2, TM and Gal-3 in serum of patients in the MACE group were significantly higher than those of control group (P < 0.05). Multivariate Logistic regression analysis showed that NT-proBNP, CLEC-2, TM, and Gal-3 were all influential factors for the occurrence of MACE after PCI in ACS patients (P < 0.05).
NT-proBNP, CLEC-2, TM and Gal-3 are influencing factors for MACE in patients with ACS after PCI, and have a good predictive role in evaluating the occurrence of MACE.
[1] |
BHATT D L, LOPES R D, HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes: a review[J]. JAMA, 2022, 327(7): 662-675. doi: 10.1001/jama.2022.0358
|
[2] |
VIRANI S S, ALONSO A, BENJAMIN E J, et al. Heart disease and stroke statistics-2020 update: a report from the American heart association[J]. Circulation, 2020, 141(9): e139-e596.
|
[3] |
TOWASHIRAPORN K, KRITTAYAPHONG R. Current perspectives on antithrombotic therapy for the treatment of acute coronary syndrome[J]. Int J Gen Med, 2022, 15: 2397-2414. doi: 10.2147/IJGM.S289295
|
[4] |
ARORA S, STOUFFER G A, KUCHARSKA-NEWTON A M, et al. Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction[J]. Circulation, 2019, 139(8): 1047-1056. doi: 10.1161/CIRCULATIONAHA.118.037137
|
[5] |
BHATT D L. Percutaneous coronary intervention in 2018[J]. JAMA, 2018, 319(20): 2127-2128. doi: 10.1001/jama.2018.5281
|
[6] |
VAN OOSTERHOUT R E M, DE BOER A R, MAAS A H E M, et al. Sex differences in symptom presentation in acute coronary syndromes: a systematic review and meta-analysis[J]. J Am Heart Assoc, 2020, 9(9): e014733. doi: 10.1161/JAHA.119.014733
|
[7] |
GUO G F, HUANG Z Q, WANG S X, et al. Sex differences in uric acid and NT-pro BNP assessments during coronary severity[J]. Medicine, 2020, 99(15): e19653. doi: 10.1097/MD.0000000000019653
|
[8] |
WANG J L, GUO C Y, LI H W, et al. Prognostic value of NT-proBNP in patients with successful PCI for ACS and normal left ventricular ejection fraction[J]. Am J Med Sci, 2022, 363(4): 333-341. doi: 10.1016/j.amjms.2021.10.017
|
[9] |
郑青, 鲍逸民, 陈宁琳, 等. 生物标志物水平预测急性冠脉综合征PCI治疗后早期心血管事件的临床意义[J]. 实用临床医药杂志, 2015, 19(24): 1-4, 8. doi: 10.7619/jcmp.201524001
|
[10] |
WATANABE-KUSUNOKI K, NAKAZAWA D, ISHIZU A, et al. Thrombomodulin as a physiological modulator of intravascular injury[J]. Front Immunol, 2020, 11: 575890. doi: 10.3389/fimmu.2020.575890
|
[11] |
GIRI H, PANICKER S R, CAI X F, et al. Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells[J]. Proc Natl AcadSci U S A, 2021, 118(11): e2022248118. doi: 10.1073/pnas.2022248118
|
[12] |
MENG D Y, LUO M, LIU B B. The role of CLEC-2 and its ligands in thromboinflammation[J]. Front Immunol, 2021, 12: 688643. doi: 10.3389/fimmu.2021.688643
|
[13] |
DANGELMAIER C, VARI H R, WRIGHT M, et al. Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets[J]. Res PractThrombHaemost, 2022, 6(3): e12710.
|
[14] |
ROTSHENKER S. Galectin-3 (MAC-2) controls phagocytosis and macropinocytosis through intracellular and extracellular mechanisms[J]. Front Cell Neurosci, 2022, 16: 949079. doi: 10.3389/fncel.2022.949079
|
[15] |
SREJOVIC I M, IUKIC M L. Galectin-3 in T cell-mediated immunopathology and autoimmunity[J]. Immunol Lett, 2021, 233: 57-67. doi: 10.1016/j.imlet.2021.03.009
|
[16] |
CAO Z Q, YU X, LENG P. Research progress on the role of gal-3 in cardio/cerebrovascular diseases[J]. BiomedecinePharmacother, 2021, 133: 111066.
|
[17] |
KHAN S, RASOOL S T. Current use of cardiac biomarkers in various heart conditions[J]. EndocrMetab Immune Disord Drug Targets, 2021, 21(6): 980-993. doi: 10.2174/1871530320999200831171748
|
1. |
范静,端木玉娟,张异. 中西医结合循证护理在消化内镜下治疗胃肠息肉患者中的应用效果. 河南医学研究. 2023(07): 1322-1326 .
![]() |